WallStSmart

Novartis AG ADR (NVS)vsRecursion Pharmaceuticals Inc (RXRX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 83972% more annual revenue ($57.36B vs $68.23M). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

RXRX

Hold

35

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -0.84
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-67.6%)

Margin of Safety

-67.6%

Fair Value

$95.76

Current Price

$160.50

$64.74 premium

UndervaluedFair: $95.76Overvalued

Intrinsic value data unavailable for RXRX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

RXRX3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
258.5%10/10

Revenue surging 258.5% year-over-year

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

RXRX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-54.6%2/10

ROE of -54.6% — below average capital efficiency

Free Cash FlowQuality
$-77.81M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bull Case : RXRX

The strongest argument for RXRX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 258.5% demonstrates continued momentum.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Bear Case : RXRX

The primary concerns for RXRX are EPS Growth, Profit Margin, Return on Equity.

Key Dynamics to Monitor

NVS profiles as a value stock while RXRX is a hypergrowth play — different risk/reward profiles.

RXRX carries more volatility with a beta of 1.15 — expect wider price swings.

RXRX is growing revenue faster at 258.5% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (48/100 vs 35/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Recursion Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.

Want to dig deeper into these stocks?